Genetic Technologies presents data on colorectal cancer risk prediction model

Genetic Technologies announces a poster presentation by Dr Erika Spaeth at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend. The Poster titled "Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk" was authored by GTG’s Science Team including Erika Spaeth, Aviv Gafni, Richard Allman and Gillian Dite. Highlights: The poster demonstrates improved performance, identifying patients at risk of developing colorectal cancer by expanding number of SNPs from 45 to 144. The patients in the top risk category showed a 27% improvement compared with the 45 SNP geneType model. The improved performance was consistent across multiple genetic ancestries, greatly improving the utility of the test leading to increased surveillance in high risk patients. The poster builds on an earlier publication by GTG that validated the geneType model, focusing on its ability to stratify patients at higher risk of developing one of the world’s most common cancers. The poster demonstrated a significant improvement in predicting a patient’s risk of developing colorectal cancer by expanding the number of genetic markers, commonly called Single Nucleotide Polymorphisms used as an important element of GTG’s geneType Risk Assessment Test for colorectal cancer. Simon Morriss, CEO of GTG, added, "The health economics demonstrated by our geneType breast cancer risk assessment test Budget Impact Model provide a pathway to reimbursement for the company’s enhanced risk assessment test for colorectal cancer. The team at GTG continue to build a strong, relevant portfolio of risk assessment tests that enable patients, or those individuals with an increased risk of developing disease, to navigate treatment options, implement disease prevention strategies and make lifestyle changes to reduce the risk of disease development."